WebMD Health News
Nov. 1, 2013 -- The cholesterol-lowering drug Crestor (rosuvastatin) was the nation's most prescribed drug in the past 12 months, according to a new report from research firm IMS Health. New "...
No specific treatment of overdosage with LIPTRUZET can be recommended. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.
In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, 40 mg/day to 18 patients with primary hyperlipidemia for up to 56 days, and 40 mg/day to 27 patients with homozygous sitosterolemia for 26 weeks, was generally well tolerated. One female patient with homozygous sitosterolemia took an accidental overdose of ezetimibe 120 mg/day for 28 days with no reported clinical or laboratory adverse events.
Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.
Active liver disease or unexplained persistent elevations of hepatic transaminase levels.
Hypersensitivity to any component of LIPTRUZET [see ADVERSE REACTIONS].
W omen who are pregnant or may become pregnant. LIPTRUZET may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of LIPTRUZET use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. LIPTRUZET should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes pregnant while taking this drug, LIPTRUZET should be discontinued immediately, and the patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations].
Nursing mothers. It is not known whether atorvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPTRUZET treatment should not breast-feed their infants [see Use In Specific Populations].
Last reviewed on RxList: 5/29/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Liptruzet Information
Report Problems to the Food and Drug Administration
Tips to keep it under control.